

1 December 2005

USA Monitoring Business Update

Following on from yesterday's Annual General Meeting, the Directors of Medical Monitors Limited ("MDM") have been notified by Primedical International, Plc, ("Medpri"), the exclusive holder of license and distribution rights for Medical Monitors' products and service for the USA, that Medpri has appointed a new CEO to its subsidiary iCardia Healthcare Corporation in Chicago.

Mr David Stanley takes on the position of CEO at iCardia with more than 26 years of experience in sales and marketing in the US healthcare and medical devices sector. This has included the management of more than 170 sales rep's in a company that he grew and on-sold to the largest 'physicians clinic' products distribution organisation. Coincidentally, iCardia has contracted with the same organisation to distribute and sell its *suPER*[™] ECG monitoring units and service across the USA. Medpri directors believe that Mr Stanley is well placed to significantly grow the iCardia ECG monitoring business over the coming months.

As previously stated, MDM has supplied the initial order of 5,000 *suPER*[™] ECG monitoring units to iCardia with a further 15,000 units manufactured and delivered as ordered - which iCardia has then supplied to its contracted national sales distributor. Medpri has informed MDM that more than USD\$600,000 (AUD\$800,000) has been generated in related service fees over this calendar year. Medpri has further confirmed that its USA monitoring business is ahead of budget and that it has secured contracts to supply *suPER*[™] ECG units and service to a number of major medical clinics. These clients include some of the most prestigious and leading cardiology clinics in the USA.

Medical Monitors will have direct benefit through its supply of product, and with its major equity position in Medpri.

Medical Monitors' technology and service model remain superior to the current market offerings in transtelephonic (telephone transfer) cardiac monitoring, and the company is well placed to take a substantial share of the lucrative US arrhythmia monitoring market estimated to be more that USD\$550 million per annum. This technology, which allows doctors to remotely monitor the cardiovascular health of their patients, has already been granted United States Food and Drug Administration (FDA) notification to enable marketing and sales.

For further information, please contact Dr Allan Shell on (02) 9344 8100.